SCHEMBL25725979

SCHEMBL25725979

CNc1cc(Cl)c(C)cc1NC(=O)/C=C/c1cccnc1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 19/20 0.59
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25722346 0.93 NAMPT (0.58) NAMPTNPC1RAB9A
SCHEMBL25725288 0.92 NAMPT (0.54) NAMPTNPC1RAB9A
SCHEMBL25723176 0.87 NAMPT (0.50) NAMPTNPC1RAB9A
SCHEMBL25725265 0.87 NAMPT (0.59) NAMPTNPC1RAB9A
SCHEMBL25724174 0.86 NAMPT (0.50) NAMPTNPC1RAB9A
SCHEMBL25725946 0.86 NAMPT (0.50) NAMPTNPC1RAB9A
SCHEMBL25722348 0.84 NAMPT (0.56) NAMPTNPC1RAB9A
SCHEMBL25722352 0.81 NPC1 (0.59) NAMPTNPC1RAB9A
SCHEMBL25725290 0.81 NAMPT (0.57) NAMPT
SCHEMBL25722338 0.79 NAMPT (0.58) NAMPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202980-A1 N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202980-A1 N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer SALL4, GLI2, GLI1 NAMPT 1176/4885NPC1 3763/4885RAB9A 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback